Skip to contentSkip to footer

Tag: ozempic


Novo Nordisk and Eli Lilly Struggle to Meet Skyrocketing Demand for Ozempic, the Revolutionary Drug Tackling Obesity

Novo Nordisk and Eli Lilly in meeting the high demand for their GLP-1 class diabetes and anti-obesity drugs, particularly Ozempic. Despite strong sales, they struggle with supply shortages, partly due to contamination at a US site and the rise of counterfeit versions. This has led to health risks and legal challenges. The shortage has prompted…

Read more